© Reuters. FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo
By Manojna Maddipatla and Mrinalika Roy
(Reuters) -Eli Lilly on Tuesday said it has started the application process for a U.S. approval of its closely watched experimental Alzheimer’s drug and expects regulatory decision by the second half of 2022, potentially setting it up against rival Biogen (NASDAQ:BIIB)’s recently approved Aduhelm.
Lilly said it has started a real-time submission for its donanemab to the U.S. Food and Drug Administration for accelerated approval for use in early Alzheimer’s disease.
Biogen used the same regulatory pathway, which requires a study to confirm the drug works as intended against the fatal mind-wasting disease, to get approval for its treatment in June.
Lilly said that even if it secured expedited approval based on mid-stage trial data, it expected to see modest uptake of the drug until full data from an ongoing late-stage trial becomes available. The company said it expected data from the larger study by mid-2023.
The note of caution appeared to weigh on Lilly’s shares, which shares have risen 45% this year through Monday’s close largely due to optimism around its Alzheimer’s treatment.
The shares were marginally higher in choppy trading after early gains following the group’s upgraded profit outlook for 2021 and mixed third-quarter earnings report that showed a rise in sales of its COVID-19 antibody therapies, but also increased costs of developing some of its drugs denting profits.
Mizuho analyst Vamil Divan said the timeline for regulatory decision along with the company’s initial expectations for its launch could be playing a role in the stock’s weakness.
The drugmaker, best known for its anti-depressant Prozac, is betting on new drug approvals to drive growth and offset competition for key drugs like insulin products Basaglar and Humalog and pricing pressures in the U.S. market.
The company raised its forecast for this year’s adjusted earnings per share to between $7.95 and $8.05 from an earlier $7.80 to $8.00 range, despite missing third quarter profit estimates.
Lilly also said it had launched a head-to-head study comparing its donanemab to Biogen’s Aduhelm to assess which drug was more effective in clearing brain amyloid plaque deposits, which is likely to benefit patients with Alzheimer’s disease.
Lilly kicks off application for Alzheimer’s drug U.S. approval
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.